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Abstract
Since the inception of global gene expression proﬁling platforms in the mid-1990s, there
has been a signiﬁcant increase in publications of differentially expressed genes in the
process of epileptogenesis. In particular for mesial temporal lobe epilepsy, the presence of a
latency period between the ﬁrst manifestation of seizures to chronic epilepsy provides the
opportunity for therapeutic interventions at the molecular biology level. Using global
expression proﬁling techniques, approximately 2000 genes have been published demon-
strating differential expression in mesial temporal epilepsy. The majority of these changes,
however, are speciﬁc to laboratory or experimental conditions with only 53 genes demon-
strating changes in more than two publications.To this end, we review the current status of
gene expression proﬁling in epileptogenesis and suggest standard guidelines to be followed
for greater accuracy and reproducibility of results.
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INTRODUCTION
The understanding of epilepsy as a complex interaction between
numerous excitatory and inhibitory neuronal connections inﬂu-
enced at the molecular level rightly brings about focus to global
changes in the entire transcriptome in the epileptogenic process.
Annotating the individual genomic changes at speciﬁc time points
deliversonlyasnapshotofamuchlargerprocess.Thedevelopment
of global gene expression proﬁling platforms has revolutionized
molecular biological research, allowing vast amounts of informa-
tion to be identiﬁed, catalogued and measured. Genomic changes
are seen in concert giving the potential for a broader understanding
of the disease process.
The late 1990s heralded the development of several important
technological advances in molecular biological research. DNA
microarray and serial analysis of gene expression (SAGE) were
introduced allowing comparisons of global gene expression utiliz-
ing differing conditions in laboratory experimentation. This has
allowed the relatively new ﬁeld of comparative genomics to ﬂour-
ish (43, 54). With respect to the brain, patterns of gene expression
have been reported as early as 1999 with comparative libraries
generated between malignant glioma tissue and normal brain for
SAGE, and between sleep–wake cycles for microarray (40, 55).
From this point there has been an explosion of genomic informa-
tion with steadily increasing reports generated during development
and aging (38, 94, 106), malignant brain processes (37, 101), neu-
rodegenerativedisorders(41,58),behavioral(12,45)andanatomi-
cal studies (18). Studies into epileptogenesis have also expanded
since the ﬁrst global gene expression studies into epilepsy in 2001
(29, 42). For this reason we will review the published papers and
discuss the usefulness of global transcriptome analyses with
regards to epileptogenesis.
EPILEPSY AND EPILEPTOGENESIS
Epilepsy is a disorder of the brain characterized by an enduring
predisposition to generate epileptic seizures and by the neurobio-
logical, cognitive, psychological and social consequences of this
condition. An epileptic seizure is a transient occurrence of signs
and/or symptoms caused by the abnormal excessive or synchro-
nous neuronal activity in the brain (27). It includes seizures occur-
ring in the absence of a recognized cause as well as events occur-
ring in patients with antecedent stable (non-progressing) central
nervous system insults (unprovoked seizures), but excludes sei-
zures occurring in a close temporal relationship with an acute
systemic, toxic or metabolic insult, which is expected to be the
underlying cause (provoked seizures) (28).
Within the broad classiﬁcation of epilepsy, mesial temporal lobe
epilepsy (MTLE) is the most common location-related epilepsy.
This may be lesional or non-lesional, with the great majority of
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ampal sclerosis (HS).There remains much debate in the neurologi-
cal world regarding HS as a cause or consequence of seizures.
Pathological evidence has shown the presence of HS in brains of
dementia patients without clinical epilepsy (19, 104). In addition,
MTLE patients with dual pathology may have HS that is: (i) a
non-speciﬁc result of the primary epileptogenic lesion and not in
itself epileptogenic; (ii) secondary to the primary epileptogenic
lesions but also epileptogenic; or (iii) a primary HS that coexists
with another epileptogenic lesions (109). Proponents of the initiat-
ing hit theory of epilepsy argue that the progressive nature of
MTLE demonstrates HS as a consequence of the seizure process.
Typically a variable latent period between the initial precipitating
incident and habitual unprovoked seizures is present, followed by a
silent period between the ﬁrst habitual unprovoked seizure and the
onset of intractability. This strongly suggests that the pathology is
progressive (5). Worsening HS creates a cycle whereby increased
seizure severity and frequency lead to further neuropathological
changesandhenceworseningclinicalseizures.Severaltheoriesfor
the cause of HS have been proposed, with the most commonly
quoted being febrile convulsions. Other theories include vascular
injuries and developmental abnormalities. It is this process of pro-
gression to seizures of worsening severity with increasing fre-
quency that is termed epileptogenesis (Figure 1).
HS was ﬁrst described in 1825 by Bouchet and Cazauvieil (8). It
is a pathological diagnosis although advances in neuroimaging
throughmagneticresonanceimaginghadallowedtheuseofradiol-
ogy as a supporting or diagnostic tool. The pathological diagnosis
consists of atrophy of the hippocampal formation with loss of
neurones and reactive gliosis in CA1, CA4 and the dentate gyrus.
In CA4, there is a loss of polymorphic neurons and pyramidal
neurons. CA3 shows some neuronal loss, but CA1 always shows
signiﬁcant neuronal loss that may be very severe. There is a vari-
able degree of gliosis seen in these subregions and occasional
vessel sclerosis has been described. Loss of granule cells in the
dentate gyrus is variable, as is gliosis. Granule cell distribution is
often disrupted and various patterns including dual lamination or
dispersionaredescribed.Sproutingofthemossyﬁbersysteminthe
dentate gyrus is apparent with Timm’s stain with many believing
that this sprouting leads to aberrant reinnervation resulting in the
hyperirritable lesion that constitutes the epileptogenic hippocam-
pus. Within all these changes, CA2 is relatively spared (68)
(Figure 2).
Treatment of non-lesional MTLE continues to be a challenge
for the epileptologist. Monodrug therapy is initially implemented
however this may progress quickly to multidrug therapy because of
continued poor seizure control. Targeted surgical excision of
the epileptogenic zone in carefully selected medically refractory
patients has been shown to improve outcome with 44% to 72% of
patients remaining seizure free compared with 4.3% to 12% of
patientsonfurthertrialsofanti-epilepticmedications(6,108,111).
Despite these ﬁgures, there remains a large proportion of epileptic
patients who continue to suffer unpredictable recurrent seizures.
Understanding the molecular biological changes underlying the
process of epileptogenesis is crucial to the development of newer,
more effective treatment regimes.
GLOBAL EXPRESSION PROFILING
PLATFORMS
SAGE and DNA microarray generate large libraries of mRNA
sequences enabling researchers to generate differential gene
expression lists in disease states by statistical comparison of tran-
script frequencies between two or more conditions. Both originally
described in 1995, the platforms have been extensively used in the
study of human disease with millions of tags analyzed and com-
pared with easily accessible online tag libraries. Massively parallel
signaturesequencing(MPSS)wasdevelopedin2000asanalterna-
tivequantitativeopen-endedplatformandhasriseninpopularityas
a research tool. A brief description of each platform follows and
comparison of their relative advantages or disadvantages can be
seen in Table 1.
Seizure
Head trauma
Initial insult Latency period Chronic epilepsy
Febrile convulsions
Perinatal hypoxia
Vascular event
- Imbalance of excitatory/inhibitory impulses
- Alterations in synaptic transmission
Permanent genomic expression change
Irreversible histological change - Changes in Ca2+ homeostasis
- Abnormal immune responses
Improved perinatal care
Preventative medicine
Monopharmacy AED
- Genomic modifying therapy
- Control of calcium release
- Blockage of excitatory impulses
- Control of immune hyper-response
- Neural stimulation
- Neural infusion devices
Occasional seizures
Controllable with oral medications
Silent molecular biological events
Polypharmacy AED
Surgical resection
Refractory seizures
↑g frequency and severity
Figure 1. Initial hit theory of epileptogenesis. Abbreviations: AED = anti-epileptic drug.
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SAGE as originally described is based on two basic assumptions:
(i) that a short nucleotide sequence tag (9–10 base pairs) contains
sufﬁcient information to uniquely identify a given transcript; and
(ii) concatenation or linking of the so-identiﬁed short sequence
tagsallowstheefﬁcientanalysisoftranscriptsinaserialmannerby
the sequencing of multiple tags within a single clone (103).
Practically, the genome of interest is interrogated from a deﬁned
four-base pair position, classically the NlaIII site. An anchoring
enzyme binds to this deﬁned complementary position and acquires
adjacent short mRNA sequences (9–10 base pairs) that, based on
the ﬁrst assumption earlier, allows speciﬁc mapping of these tran-
scripts to genomic libraries. Proportionate ampliﬁcation of differ-
enttranscriptsgivesarealisticquantiﬁcationofgeneexpressionfor
the particular experiment or disease condition (67, 103).
SAGE has been utilized extensively in the study of human
disease. In the ﬁrst 5 years since its inception, close to ﬁve million
tags had been analyzed using this method (102). It has been used in
cancer, cardiovascular and immunological studies (74, 76, 77).
Large online SAGE libraries are now freely available to the public,
with access to raw SAGE sequence data, precomputed tag extrac-
tions and several modest analysis tools. SAGEmap currently con-
tains over two million tags from 47 SAGE libraries and is currently
available at http://www.ncbi.nlm.nih.gov/sage (56).
In terms of data analysis, SAGE is extremely efﬁcient with a
complete genome investigation allowing both whole activated and
inactivated pools of gene analysis in a quantitative and qualitative
Figure 2. (L-top) Low power (2.5¥) view
demonstrating normal subiculum into CA1;
(R-top) Low power (2.5¥) view demonstrating CA1
sclerosis and sparing of CA2; (L-bottom) Low
power (2.5¥) view demonstrating neuronal loss in
CA3/4; (R-bottom) Medium power (5¥) view with
dispersion of dentate gyrus. (arrow: subiculum,
block arrow: CA1, curved block arrow: CA2, curved
arrow: CA3/4, arrow outline: dentate gyrus).
Table 1. Global platforms comparison. Abbreviations: MA = microarray; MPSS = massively parallel signature sequencing; SAGE = serial analysis of
gene expression.
SAGE MA MPSS
Global expression proﬁling platforms Yes Yes Yes
Prior knowledge of genome required No Yes No
Speciﬁcity 80% Near 100% 95%
(14 nucleotide sequence) (?Selection bias) (17 nucleotide sequence)
Sequencing error 1% <1% 7%
Unique transcipts/genes Yes No No
Quantiﬁcation Yes Yes Yes
Dataset size 20–60 000 tags Preselected tags >1 000 000 sequences
Low abundance genes Not sequenced Sequenced Sequenced
Starting mRNA concentration High High DNA megacloning
(2.5–5 mg)
Cost +++ + +
Online comparative libraries Available Available Available
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genes, thus allowing analysis and identiﬁcation of novel previously
unidentiﬁed genes/express sequence tags (ESTs) (20, 66, 67, 103).
Several possible key pitfalls have been identiﬁed in the SAGE
technique. A high amount of starting mRNA is required that is
often prohibitive and not feasible, especially in difﬁcult to obtain
human specimens or complex experimental procedures. In addi-
tion, the cost of SAGE is high and may preclude repeat experimen-
tation to verify collected data. Although SAGE studies the entire
genome, the use of a four-base pair anchoring enzyme relies on the
fact that the majority of mRNA sequences contain an anchoring
site on average every 256 base pair stretch (44 = 256).The reality is
a small proportion of mRNA will not include this anchoring site,
leading to a loss of some small fraction of mRNA from the analysis
that is extremely difﬁcult to quantify. Clearly the use of a 10-base
pairsequencetomapgeneassignmentmaycauseissuesintermsof
speciﬁcityandsensitivity.Itisnotuncommonformultiplegenesto
share the same tag or for a single gene to be mapped by multiple
tags.
There have been several modiﬁcations to the original SAGE
technique aimed at addressing the potential pitfalls. MicroSAGE
and SAGE-Lite were developed to allow lower amounts of starting
mRNA to be used allow signiﬁcantly smaller amounts of human or
animal specimens to be examined (76, 78), whereas LongSAGE
and Robust-LongSAGE were developed to improve tag or gene
mapping by generating tags of 21 base pairs as opposed to 14 (35,
85, 105).
Microarray
Microarrays are ordered samples of DNA with each sample repre-
sentingaparticulargene.Thesearraysarethenassayedforchanges
in gene expression following experimental treatment or in different
disease states. It allows simultaneous monitoring of thousands of
genes, thus providing a functional aspect to sequence information
in a given sample (23). There are several types of microarray
technologies currently in use with studies using oligonucleotide
microarray technology, the most common for high-throughput
quantitative studies of RNA expression (47). In this instance, RNA
extracted from the material of interest is reverse transcribed to
complementary DNA and incubated with a mixture of ﬂuores-
cently labeled markers at set conditions on a microarray chip con-
taining a predetermined set of genes. Quantiﬁcation is then per-
formed by computerized measurements of ﬂuorescent intensities.
It was ﬁrst described by Schena et al in 1995 who purported it to
be a method for quantitative measurement of expressed genes (88).
Schena et al utilized the EST database (7) freely released from the
National Center for Biotechnology Information that at the time
contained a total of 322 225 entries, including 2 555 645 from the
human genome. As of June 2, 2006 this count had increased to
36 750 628 total entries including 7 741 746 from the human
genome and 4 719 380 from the mouse genome.
Microarray is a relatively simple procedure to perform and is
becoming a standard technology for research laboratories world-
wide. They allow testing of thousands of genes simultaneously
with quantiﬁcation of differential expressions at a reasonable cost
when compared with SAGE. However, microarray technology
relies on prior knowledge of the genes to be identiﬁed with the
possibilityofselectionbiasduringcreationofthecDNAarray.Asa
result, novel genes are not able to be identiﬁed. Second, the amount
of starting material required was also prohibitively high in the
initial stages. This has largely been addressed with a two-stage
hybridizationprocessorglobalRNAampliﬁcationpriortorunning
the array (73, 100).
MPSS
MPSS was developed by Brenner et al in 2000 to address the vari-
abilities,costandscaleofeffortrequiredbyotherhigh-throughput,
genomic proﬁling methods. It utilizes the technology of DNA
megacloning in combination with non-gel-based signature
ﬂuorescence sequencing to generate very large numbers of short
read-length sequences (9).This process of megacloning allows the
invitrocloningoffragmentsofcDNAontomicrobeadsasopposed
to biological hosts. Millions of cDNA fragments can be cloned by
hybridizationofuniquelytaggedmoleculestomicrobeadscarrying
106 complementary sequences to each oligonucleotide primer used
(10).
MPSShasbeenusedtocreatelargedatabasesofgeneexpression
in adult human tissues (50). These have proved complementary to
other database sets published using Affymetrix chip technology
(89, 92, 93). It has been used to document the transcriptome in
human disease states including oncology (49, 61), renal disease
(30) and neuroembryology (11).
Similar to SAGE, massively parallel signature processing does
not require previous knowledge of any sequence to allow analysis.
The only requirement is that the microbead library is constructed
large enough to contain nearly all sequences from the library to be
compared against. It is time efﬁcient with simultaneous screening
of all genes and counts virtually all mRNA molecules. The librar-
ies created are more speciﬁc as MPSS generates a 17-nucleotide
signature length (95% unique) as compared with a 14-nucleotide
signature length (80% unique) in a conventional SAGE. MPSS
also allows the creation of an extremely large data set of signature
sequences (>1 000 000) by providing a depth of analysis that
allows low abundance genes to be accurately quantiﬁed, some-
thing that SAGE has been criticized for missing with datasets
being comprised of only 20 000 to 60 000 sequenced mRNAs (9,
83).
Quantiﬁcation of sequences is possible as MPSS generates a
digital output. Differential expression comparisons can be formed
with ease between samples with detection levels for statistical sig-
niﬁcance possible even with low abundance genes expressed at 30
to 40 copies per million. In contrast, hybridization techniques
requirereplicationofexperiments,highabundancegenesandlarge
differences to provide adequate quantiﬁcation (83).
Reproducibilityofthelevelsofgeneexpressionisgenerallyvery
good for signatures detected in all samples. However, cases with a
zero signature count have been noted to demonstrate a signiﬁcantly
higher error rate than those with non-zero ﬁgures. It remains
unknown as to whether this represents a true measurement or the
absence of measurement. In cases with conﬂicting values (ie, one
MPSS run claiming a value and the other claiming zero), the trends
obtained by ignoring the zero measurements within runs of the
same sample, are shown statistically to be closer to the ideal unbi-
ased comparisons between two samples. As such, taking the
maximum number of two runs has been suggested (83, 91).
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Seizure induction and epileptogenesis have been modeled exten-
sively in animals. Epileptogenic substances such as alumina gel,
penicillin, bicuculline, kainic acid, tetanus toxin, pentylenetetrazol
and pilocarpine were directly injected to induce a primary focus of
epileptogenic activity in the immediate area of placement with
corresponding marked neuronal loss and gliosis, a process termed
chemical kindling (60, 70).This was more often than not accompa-
nied by behavioral seizures including status and subsequent spon-
taneous seizures, and is also described as the “status epilepticus
models.” Other methods include the electrical kindling models ﬁrst
described by Goddard et al in 1967, whereby repeated stimulation
of selected regions of the mesial temporal lobe structures result in
behavioral seizures and the classical neuropathological changes
seen in the human MTLE. The electrical kindling models also
demonstrate seizures with progressive increase in frequency and
severity following prolonged stimulation. A chronic increase in
seizure susceptibility is seen; however, in contrast to the status
epilepticus models, spontaneous seizures are unusual and not
expected.
Status epilepticus models
Status epilepticus models of epileptogenesis are widely used as a
model of acute epileptogenesis following the application of chemi-
cal kindling. It becomes a useful model of chronic epileptogenesis
with the appearance of spontaneous seizures at a time point distant
to the initial convulsive event.This model demonstrates the classi-
cal progression of human temporal lobe epilepsy with an initial
convulsive event leading to seizures and status epilepticus before a
latency period of varying length and appearance spontaneous sei-
zures following this.Advocates of this model point to the presence
of a latency period as the period of opportunity, whereby interrup-
tionoftheepileptogenicprocessduringthistimemaybringabouta
stop in the progression of spontaneous seizures. The difﬁculty lies
in measuring the duration of each animal’s individual latency
period and hence the optimal time point for intervention and study.
The duration of latency is known to be related to the convulsant
dose with higher doses yielding shorter onset latencies (39).
Current ﬁgures suggest a mean onset latency of around 40 days;
however, shorter periods have been described (32). As such, esti-
mates of latency periods used in research studies vary from 8 to 50
days.
Mathern et al performed the only electrophysiological study
looking into the time course of hippocampal interictal spike fre-
quency after intrahippocampal kainite injection and correlated this
with histopathological changes. Four stages were classiﬁed from
this with: (i) the acute phase relating to the ﬁrst 10 days after
kainite-induced status epilepticus; (ii) the active phase from days
10to30;(iii)thelatentphaserelatingtothelatencyperiod(days30
to 90); and (iv) the chronic phase with the development of chronic
hippocampal seizures (after 90 days). Interictal spike frequency
was noted to drop during the latent phase and increase again during
the chronic stage in concert with the development of behavioral
seizures, neuronal loss and mossy ﬁber sprouting. (69)
Status epilepticus models also demonstrate a varying clinical
response of the animal subjects to differing doses of convulsive
agents.A high mortality rate is not unexpected and severe neuronal
loss is often encountered histologically. Initial seizures are unpre-
dictable in their duration and severity and may be difﬁcult to
control.Acuteantiseizuremedicationssuchasbenzodiazepinesare
often needed to bring about a cessation of the status epilepticus
state. It is clear, however, that the onset of spontaneous seizures is
directly related to the duration of the status epilepticus state and at
least 30 minutes duration of initial status epilepticus is required for
manifesting an epileptogenic process (53).
Electrical kindling models
Kindling as reported by Goddard (34) refers to the repeated admin-
istrationofsubconvulsiveelectricalstimuliresultinginprogressive
development of seizure activity traditionally performed using daily
stimulations.The term is therefore quite speciﬁc to low level elec-
trical stimulation. Numerous alterations in stimulating paradigms
have been used since Goddard’s initial description of kindling and
it is now well established as a chronic animal model of MTLE. It is
accepted as a functional model of epilepsy where altered neuronal
response develops in the absence of the gross morphological
damage seen in many other epilepsy models.
Thediscoveryofelectricalkindlingplacedtheprocessofepilep-
togenesis under greater control by the experimenter. The initial
electrical kindling current stimulus was applied to a deﬁned area
andwas,bydeﬁnition,subconvulsive(33,34).Withrepeatedappli-
cation of the electrical stimulus once or twice a day for only
seconds at a time, electrical afterdischarges were observed to
appear and gradually lengthen, and recordable after-discharges
were observed to broaden in origin from adjacent brain regions to
more distant regions and eventually the opposite hemisphere. In
addition to this electrical progression, a behavioral progression of
seizure activity occurred commencing with focal seizure activity
typically manifested as initial facial clonus contralateral to the side
of stimulation after a short delay. Progression through a stepwise
series of more overt and eventually generalized seizures follows.
This behavioral progression has been assigned a grading system,
from grade 1 to 5 by Racine (81) in his study of amygdala kindling
in rats.An animal may be regarded as fully kindled after manifest-
ing a number of grade 5 seizures.
There are many advantages of the kindling model for epilepsy
research. Development of chronic epileptogenesis by a precise
focal activation of the target brain site is readily achieved with no
mortality and very little morbidity.The pattern of seizure propaga-
tionandgeneralizationisreadilymonitoredandinterictal,ictaland
postictal periods are easily manipulated. Furthermore, the absence
of the classical neuropathological changes and placement of the
stimulating electrode at an area distant from the anatomical area of
interest (eg, amygdala kindling for investigation of hippocampal
pathology) ensures genomic expression studies are as unadulter-
ated as possible.
Kindling experiments, however, are relatively labor-intensive,
requiring a two-stage electrode implantation–electrical kindling
process usually spaced over 1 to 2 weeks. Stimulation paradigms
are also spaced over minutes to days and may take months to
reach the fully kindled state. The ideal animal model for human
temporal lobe epilepsy would consist of similar pathology, a
latent period after the initial insult appropriate for the species, a
state of chronic hyperexcitability and the emergence of spontane-
ous seizures after a latent period (107). The absence of a true
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Latency is seen from the ﬁrst kindling stimulation to the eventual
appearance of seizures; however, additional insults in the form of
further electrical stimuli are being provided leading up to and
merging with the evoked seizures. Electrical kindling also does
not produce spontaneous seizures, unless prolonged kindling is
performed. This is coined the “over-kindling” model (79). In this
model continued electrical stimulation is given beyond the stan-
dard stage-5 criterion of the fully kindled state. The number of
additional stimulations is extremely variable with recent reports
suggesting at least an additional 90 to 100 kindled seizures
required in rats for recurrent spontaneous seizures to occur
(71, 87).
Neuropathological changes in animal models
Similar to human changes there may be considerable variability in
neuropathological changes. Status epilepticus models classically
demonstrateconcordanthumanhistologicalchangesofsevereneu-
ronalloss,granulecelldispersion,remodelingofmossyﬁberstruc-
turesandneurogenesis.Thedegreeofneuronallossisrelatedtothe
concentration of inciting agent and duration of status epilepticus.
Neurogenesis has been reported without corresponding cell death
whereas granule cell dispersion may occur without evidence of
neurogenesis (72, 98).
Electrical kindling models typically do not demonstrate evi-
dence of neuronal loss, the advantage of which is purported of
enabling focused study into the effects of seizures alone without
the changes associated with cell death.
GLOBAL GENE EXPRESSION AND
EPILEPSY
An increasing number of laboratory and clinical studies involving
MTLE have been published since the inception of global expres-
sion proﬁling platforms. Prior to this the focus of each laboratory
was limited to one or a few genes selected by hypotheses generated
from the available literature or laboratory experience, using con-
ventional molecular biological techniques. These global expres-
sion studies are summarized in Table 2.
Gene expression in epileptogenesis
Microarray
The predominant proﬁling platform utilized in global expression
proﬁling of epilepsy and epileptogenesis has been microarray. A
Pubmed search utilizing the terms “microarray” and “epilepsy” or
“seizures” revealed 49 reports from which there were 10 articles
publishing results of global expression proﬁling in models of
MTLE. Bibliographic review of these articles revealed an addi-
tional two articles giving a total of 12 reports.
The majority of microarray papers published with regard to epi-
leptogenesis involve chemical kindling. These differ in terms of
Table 2. Papers. Abbreviations: 2DE = two-dimensional electrophoresis; MTLE = mesial temporal lobe epilepsy; RT-PCR = real-time polymerase chain
reaction; SAGE = serial analysis of gene expression.
Author Year Species Model Platform Differential genes Time-points
Sandberg et al 2000 Mouse Pentylenetetrazole kindling Microarray 12 or 49 out of 13 069 1 h
Liang et al 2001 Mouse Rapid amygdala kindling Differential display 26 out of 30 000 bands 0.5 h, 1 day
RT-PCR 1 week, 1 month
Hendriksen et al 2001 Rat Angular bundle kindling SAGE 79 out of ~6000 8 days
Potschka et al 2002 Rat Amygdala kindling MPSS 264 out of 5696 2 h
Tang et al 2002 Rat Kainate kindling Microarray 276 out of 3869 1 day
Elliott et al 2003 Rat Pilocarpine Kindling Microarray 129 out of 8000 14 days
Becker et al 2003 Rat Pilocarpine Kindling Microarray ~400 or 700 out of 8799 3 days
~50 or 400 out of 8799* 14 days
Lukasiuk et al 2003 Rat Amygdala kindling Microarray 282 out of 5000 1, 4 and 14 days
Arai et al 2003 Rat Ihara epileptic rat SAGE 21 out of ~3800 Chronic
Hunsberger et al 2005 Rat Kainate kindling Microarray 99 out of 1561 24 h
Wilson et al 2005 Rat Kainate kindling Microarray 9 out of 23 (neuropeptide
probes only)
1, 6, 24, 72 and 240 h
Gorter et al 2006 Rat Dentate gyrus kindling Microarray CA3 Entorhinal
2178 2548 24 h
1400 2240 1 week
1236 682 3–4 months
(out of 10 179)
Jamali et al 2006 Human MTLE Microarray 6 out of 2000 Chronic
Arion et al 2006 Human MTLE Microarray 70 out of 14 500 Chronic
Ozbas-Gerceker et al 2006 Human MTLE SAGE 146 out of ~9500 Chronic
Greene et al 2007 Rat Pilocarpine Kindling 2DE Heat shock protein B1 2 days
Liu et al 2008 Rat Pilocarpine Kindling 2DE 41 unique proteins 12, 72 h
Eun et al 2008 Human MTLE 2DE Mitochondrial SOD Chronic
Global Expression Proﬁling in Epileptogenesis Wang et al
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anatomical region investigated. Sandberg et al in 2000 demon-
strated mouse strain-speciﬁc differences in response to pentylene-
tetrazole kindling; however, this study focused on the changes
invoked early in the response to a single seizure and gives limited
insight into the actual process of epileptogenesis.
Of more relevance are the three studies by Elliott et al in 2003,
Becker et al and Tang et al, which in addition to characterizing
genomic changes in response to chemical kindling (pilocarpine:
Elliott, Becker; kainic acid: Tang), directly compared the genomic
expression changes with certain physiological and disease states.
Inthismanner,severalassertionsweremade.Elliottet alsuggested
support for the hypotheses of parallels existing between gene
expression underlying development and epileptogenic plasticity
duringthelatencyperiodfollowingcomparisonswiththeadultand
developing rats (4, 24, 95).
Directcomparisonofthegenomicresponsesofbraininresponse
to ischemic stroke, intracerebral hemorrhage, kainic acid induced
seizures, hypoglycemia and hypoxia was made by Tang et al in
2002. Signiﬁcantly, marked overlap of regulated genes was found
throughout all disease states. In particular, all genes induced by
kainic acid were also induced by ischaemia, hemorrhage or
hypoglycemia.This suggests a multifactorial mechanism of injury
for kainic acid induced seizures that mimics or utilizes the same
pathways as those associated with ischaemia, hypoglycemia or
hemorrhage (95). Whether seizures themselves primarily induce
these genomic changes or secondarily act through periods of
ischemic or hypoglycemic during seizure episodes remain unclear.
What is clear, however, is the similarities in histological changes
seen in these conditions with marked neuronal loss, ﬁbrillary
gliosis with vacuolation and enlarged reactive astrocytes variously
reported following severe hypoglycemia and ischemia, with or
without associated status epilepticus (1, 13, 51, 52).
Becker et al correlated temporal changes of genes associated
with cellular stress and injury at 3-day post-status epilepticus,
genes associated with cytoskeletal and synaptic reorganization at
14-day post-status epilepticus, and genes involved in neurotrans-
mission pathways at the chronic epilepsy stage. This study also
provided the ﬁrst comparison with human hippocampal specimens
with eighteen genes differentially expressed in both the chronic
stage of pilocarpine induced epilepsy and medically refractory
MTLE (4).
Other experimental microarray studies investigated changes of
growth factor signaling genes, transcription factors, angiogenesis
signaling molecules, neuropeptides, neuronal plasticity and signal
transduction using custom-made probe sets at varying time points.
These are summarized in Table 2 (44, 63, 110).
The electrical kindling model was utilized by Lukasiuk et al to
investigate the gene expression changes during speciﬁc phases of
epileptogenesis with the hypothesis that remodeling of neuronal
circuits underlying epilepsy is associated with altered gene expres-
sion during epileptogenesis. RNA was extracted from the hippoc-
ampus and temporal lobe at 1, 4 and 14 days following electrical
kindling and hybridized with cDNA arrays containing ap-
proximately 5000 rat gene probes. There were 87 differentially
expressed genes within the hippocampus with 37 genes regulated
at 1 day, 12 at 4 days and 14 at 14 days.There was an overlap of 13
genes with the temporal lobe that demonstrated 208 differentially
expressed genes in a similar time distribution as the hippocampus
genes. Functional annotation of the regulated genes revealed genes
involved in neuronal plasticity, gliosis, organization of the cytosk-
eleton or extracellular matrix, cell adhesion, signal transduction,
regulation of cell cycle and metabolism (63).
SAGE
A literature search using the words “serial analysis of gene expres-
sion” and “epilepsy” and/or “seizures” produced four articles.Two
articles were published from the same laboratory with one expand-
ing on the initial report, whereas the other two studies involved
human MTLE and the use of a genetically modiﬁed epileptic rat,
the Ihara rat.
There is only one published SAGE report using the rat electrical
kindling model of mesial temporal lobe. Unlike most electrical
kindling models, marked neuronal cell loss and gliosis is seen
histologically in the electrical kindling model utilized by Hendrik-
sen et al with a latent period of between 1 and 2 weeks following
electrical kindling of the angular bundle and the appearance of
spontaneous seizures. As such, hippocampal harvest was per-
formed 8 days after the ﬁnal electrical stimulation, prior to the
commencement of spontaneous seizures and during the process of
epileptogenesis.Over10 000tagswereanalyzedinbothstimulated
and control groups resulting in SAGE libraries containing
5053 and 5919 different unique tags respectively. There were 92
differentially expressed genes, predominantly associated with
ribosomal proteins, protein processing and axonal growth and glial
proliferation (42).
SAGE was also performed on hippocampi of the Ihara epileptic
rat (IER).The IER is an animal model of MTLE that demonstrates
progressive limbic seizures, eventually resulting in spontaneous
generalized tonic-clonic seizures at 5 to 6 months of age. SAGE
was performed on hippocampal tissue taken at 2 months of age and
compared with the Wister rat. Over 7000 tags were analyzed with
creation of a SAGE library for each group consisting of 2492 and
2141genes,respectively.Eighty-onedifferentiallyexpressedgenes
were identiﬁed, with genes associated with neurotransmission and
intercellular component downregulated, and genes associated with
protein synthesis, metabolism, membrane transport, the cytoskel-
eton and ion-channels upregulated (2).
Our laboratory has performed SAGE on adult male C57/BL6
mice following rapid electrical kindling of the amygdala. This
model of MTLE is useful in allowing assessment of the effect of
seizures during epileptogenesis without the confounding effects
of neuronal loss and cell death (90). RNA was extracted from
hippocampi taken 3 h following the completion of kindling with
around 28 000 tags analyzed in control and stimulated groups. In
the control group, 13 213 unique tags were identiﬁed whereas
12 302 unique tags were identiﬁed in the stimulated group. There
were 55 differentially expressed genes when comparing between
the groups with functional classiﬁcation denoting immune
response, cellular metabolism, axonal growth and regeneration,
signal transduction, ion transport, synaptic and neurotransmission
and genes of unknown identity or function predominant (Wang et
al, in preparation).
MPSS
There has been a single published report using MPSS for gene
expression studies during epileptogenesis. Potschka et al utilized
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genomic changes using MPSS. Seven thousand and four signa-
tures with a minimal occurrence of two clones in each run were
analyzed resulting in annotation of 5696 identiﬁed genes. Two
hundred sixty-four differentially expressed genes were identiﬁed
with 128 upregulated and 136 downregulated ones. The immedi-
ate early gene Homer 1A was most strongly induced at 2 h.
Identiﬁcation of this gene fueled further research into the pos-
sibilities of Homer 1A being an intrinsic anti-epileptogenic and
anticonvulsant gene upregulated as a protective measure during
epileptogenesis (80).
HUMAN STUDIES
There remains a relative dearth of global gene expression studies
involving human specimens. This is somewhat surprising given
that mesial temporal lobectomy, hippocampectomy and amygda-
lectomy is a well-accepted treatment option for medically refrac-
tory MTLE in carefully selected cases giving a readily available
source of hippocampal specimens (96). Four studies have been
reportedutilizingmicroarray(3)andSAGE(1)ofwhichonlythree
dealt with MTLE patients.
Jamali et al analyzed the entorhinal cortex from the hippocam-
pus of brains removed as a surgical treatment consisting of a stan-
dard anterior temporal lobectomy whereas Özbas-GerÇeker et al
did not differentiate between hippocampal subregions. Both
studies attempted to ﬁnd control tissue in the form of autopsy
hippocampal specimens; however, this obviously posed a signiﬁ-
cant problem in terms of reproducibility of “controls” not to
mention the ethical dilemma. In an attempt to factor in a bias
related to long-term exposure to anti-epileptic medications, Jamali
et al also compared samples from autologous adjacent lateral tem-
poralcortexthathadbeensubjectedtothesameenvironmentasthe
epileptic tissue.
Comparison of the entorhinal cortex with non-epileptic lateral
temporal lobe revealed 16 regulated genes of which 10 were
upregulatedandsixweredownregulated.Thisstudysuggesteddys-
regulation of the neurotransmission and complement systems
within the entorhinal cortex as another pathway affected in the
process of epileptogenesis (46). On the other hand, the study by
Özbas-GerÇeker et al revealed 143 differentially expressed genes
that matched functionally to genes associated with basic metabo-
lism, transcription regulation, protein synthesis and degradation,
signal transduction, structural proteins, regeneration and synaptic
plasticity and genes of unknown identity or function (74).
Neither study attempted to perform a comparative approach
using animal models with their human tissue that would add valid-
ity to any prior or future reports into this topic. On the other hand,
the study by Becker et al in 2003 demonstrated complimentary
results between rat and human specimens with 18 genes regulated
in the chronic stage of the rat status epilepticus model showing
corresponding expression patterns in hippocampal subﬁelds of
patients with pharmacoresistant MTLE (4).
PROTEOMIC STUDIES
Proteomics is a technique that enables one to ﬁnd proteins changed
by the cells response to internal states, external stimulations or
developmental cortex.The technique of the two-dimensional elec-
trophoresis (2DE) allows global proﬁling of the proteomic changes
in different disease states or conditions. Two studies into chemi-
cally induced epilepsy (pilocarpine) have investigated the pro-
teomic proﬁle following epileptogenesis in the whole hippocampi
alone or in conjunction with the forebrain in rats.These suggested
upregulation of pathogenic, neuroprotective and neurogenic
responses with validation performed using Western blotting and
immunohistochemistry (36, 59).
A single study by Eun et al (25) attempted to analyze human
temporal lobe specimens in patients with MTLE undergoing surgi-
cal resection by performing 2DE and Western blotting of the
selected proteins. Control specimens were obtained from lateral
temporal cortices of patients undergoing temporal lobe operations
for tumors in the absence of seizures. This study reported signiﬁ-
cant changes in nine proteins with particular emphasis on proteins
related to oxidative stresses; it also highlights the shortcomings in
performing comparative studies in humans with control specimens
coming from a variety of different diseases such as glioblastoma
multiforme (7), sphenoid wing meningiomas (3) and malignant
lymphomas (2).
SUPPORTIVE OR CONFLICTIVE
The advent of global expression proﬁling technology has led to an
ever increasing amount of genomic information available. To the
end of 2006, there are over 1100 published reports on microarray
studies involving the brain and brain disorders, with nearly 100
SAGE studies of the same. For epilepsy studies the ﬁgures reveal
32 microarray and four SAGE studies (Figure 3).
Yet for all the additional knowledge that has been acquired, the
outcomes of epilepsy treatment, particularly MTLE, remain in the
main stagnant. There is as yet no active intervention to prevent
progression of epilepsy either from the “initial insult” to the
“latency period,” or from the latency period to chronic epilepsy.
The question follows then: what is the beneﬁt of large-scale gene
expression proﬁling? Is the accumulation of knowledge of beneﬁt
to the treating epileptologist or does it create more confusion in the
treatment of this already complex condition?
The inherent problems with analyzing and applying data gener-
ated from global expression proﬁling stems from the obvious dif-
ference in epilepsy models, the proﬁling platform used, animal
type and laboratory environment. Care must be taken in comparing
genomic proﬁles generated from differing epilepsy models.
Genomic reactions are clearly different between different species
of the same animal (86). These differences must be accentuated
even more when comparing the different proﬁles in mice, rats and
humans. Status epilepticus models of epileptogenesis possess the
advantage of a clear-cut progression from initial insult to chronic
epilepsy in contrast to electrical kindling where a predominantly
time-dependent protocol is usually administered.The rapid electri-
cal amygdala kindling model utilized in our laboratory allowed the
effects of seizures in isolation to be investigated without the con-
founding effects of neuronal loss. In contrast, status epilepticus
models of epileptogenesis demonstrate marked neuropathological
changes and may manifest widespread systemic effects.The use of
benzodiazepinestohaltprolongedseverestatusepilepticusinthese
models may also adversely alter the transcriptome.
Tang’s comparisons between kainic acid-induced seizures,
hypoxia, hypoglycemia and hemorrhage suggest that the kainic
Global Expression Proﬁling in Epileptogenesis Wang et al
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other three conditions (95). Indeed there are clear interrelations
between all such conditions with prolonged seizures resulting in
metabolic acidosis and an environment of relative hypoxia and
hypoglycemia, and prolonged and severe hypoglycemia resulting
inseizuresinthegeneralizedtonic-clonicform.Theeventualhisto-
pathological outcome from these events culminates in varying
degrees of neuronal loss, gliosis and even necrosis. If this is the
case, it is difﬁcult to proclaim that the genetic expression changes
are actually speciﬁc to the process of epileptogenesis. Another
study reported in abstract form (21) and cited in Lukasiuk et al’s
reviewrevealeddistinctdifferencesingeneexpressionbetweenthe
kainic acid and pilocarpine models of epileptogenesis, despite
beingstudiedinasexactinganenvironmentofthesamelaboratory.
The pathology of HS deserves special mention at this point. It
remains a point of controversy as to whether HS is the underlying
cause, or end result of the clinical syndrome of MTLE.As a cause,
the proposed theories underlying HS include childhood febrile
convulsions, perinatal hypoxic events or vascular accidents,
whereas as an end result it is suggested repeated seizures progres-
sively inﬂict end-organ damage, particularly in the susceptible
areas of the hippocampus described earlier. In a molecular biologi-
cal sense, a causative action would allow quantiﬁcation of gene
expression changes of each cell type whereas as an outcome,
genomic proﬁling would be representative of changes in cell
population.
Confounding the arguments are the documented cases of normal
hippocampal size and histology on positively electrophysiologi-
cally localized epileptogenic foci excised as a curative procedure
(15) as well as autopsy specimens demonstrating histological
changes consistent with HS in the absence of clinical seizures (48).
Theuniquecerebralresponsesindifferentindividualsmustbekept
in mind in all laboratory and translational research studies.
The number of published differentially expressed genes during
epileptogenesis is fast approaching 2000. On review of the avail-
able data from these publications there is minimal conformity
between the genes described. Lukasiuk et al has produced a list of
common differentially expressed genes involving models of epi-
leptogenesis, including traumatic brain injury studies (62). From
the near 2000 genes, only a small number (53) are noted to be
differentially expressed in more than one study. However, if the
gene proﬁles of traumatic brain injury studies are ﬁltered out, only
38 genes remain differentially expressed across studies. In addi-
tion, a proportion of these common genes appear to be differen-
tially expressed in conﬂicting directions.
In order to further assess the consistency of altered gene
expression across the studies we annotated the list of commonal-
ity differentially expressed genes to include studies published to
the end of 2006 as well as our currently unpublished SAGE data.
Comparisons were performed using all available published lists
as well as accessing complete gene lists made available through
online downloads. Differences in epilepsy models and global
expression proﬁling platforms were also recorded. There were 72
genes reported to be regulated during epileptogenesis in two or
more studies. Thirty-nine genes demonstrated a consistent direc-
tion of change with 15 showing conﬂicting results. The direction
of regulation could not be ascertained from the available litera-
ture in 20 genes. No genes were reported regulated in more than
ﬁve papers with the majority (50) only regulated in two papers.
The two genes consistently regulated in ﬁve reports were the
rather ubiquitous glial ﬁbrillary acidic protein and the S100-
related protein (Table 3).
Genome Animal model
Global expression experiments
Ethically approved
Readily reproducible
True representation of human disease
High translational efficacy
Specific anatomical location/subregion and
cellular type
Demonstrates consistent neuropathological
alteration
Reproducible, non-contaminated harvesting
Serial analysis of gene expression
DNA microarray
Massively parallel signaling sequencing
Immunoperoxidase staining
Western blotting
In situ hybridization
Harvest
Reverse
transcription
Transcription
mRNA Target tissue
RNA Validation qRT-PCR
Protein Proteomic
analysis
Genetic
component
Experimental
process
cDNA Global expression
platform
Figure 3. Global expression proﬁling
experiments. Abbreviations:
qRT-PCR = quantitative real-time polymerase
chain reaction.
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Gene name Abbreviation Reports Platform Conﬂicting Epilepsy model
SAGE MA Electrical
kindling
Chemical
kindling
Human IER
14-3-3 protein gamma 21 1 N o 1 1 0 0
Actin related protein 2/3 complex Arpc 31 2 N o 1 2 0 0
a-tubulin 21 1 N o 1 1 0 0
Brain derived neurotrophic factor BDNF 41 3 N o 2 2 0 0
Calponin 3, acidic Cnn3 21 1 N o 1 1 0 0
Cathepsin D Ctsd 21 1 N o 1 1 0 0
Cathepsin S Ctss 21 1 N o 1 1 0 0
Cholecystokinin CCK 31 2 N o 1 0 2 0
Chromogranin B Chgb 21 1 N o 1 1 0 0
Clone BB.1.4.1 21 1 N o 1 1 0 0
Complexin 2 Cplx2 22 0 N o 1 0 1 0
Cystatin C Cst3 42 2 N o 2 2 0 0
Ectodermal neural cortex Enc1 21 1 N o 0 0 2 0
Elongation factor-1a Efa1 21 1 N o 1 1 0 0
Epithelin 1 and 2 21 1 N o 1 1 0 0
ESTs, Hs to MBD3 21 1 N o 1 1 0 0
Ferritin heavy chain Fth 32 1 N o 2 1 0 0
Glial ﬁbrillary acidic protein GFAP 52 3 N o 1 3 1 0
Granulin Grn 21 1 N o 1 1 0 0
Growth factor receptor bound protein 2 Grb2 20 2 N o 0 1 1 0
Heat shock protein 27 Hsp27 20 2 N o 0 2 0 0
Heat shock protein 70 Hsp70 41 3 N o 1 2 1 0
Metallothionein 2 Mt2 30 3 N o 0 3 0 0
Metallothionein 3 Mt3 22 0 N o 1 0 1 0
MHC class Ib antigen 20 2 N o 0 2 0 0
Myelin basic protein Mbp 32 1 N o 1 1 1 0
NDRG family member 2 NDRG2 21 1 N o 0 0 2 0
Neural precursor expressed, developmentally
downregulated gene
Nedd 22 0 N o 1 0 1 0
p41-Arc arpD 20 2 N o 0 2 0 0
Pleckstrin Pscd1 32 1 N o 1 0 2 0
Preprocathepsin 21 1 N o 1 1 0 0
Protein p9Ka homologous to calcium-binding
protein (S100)
S100 51 4 N o 2 3 0 0
Secreted protein, acidic, cysteine-rich
(osteonectin)
SPARC 42 2 N o 1 2 1 0
Spinophilin Spn 21 1 N o 1 1 0 0
Tachykinin 1 Tac1 20 2 N o 0 2 0 0
Thyrotropin releasing hormone TRH 40 4 N o 1 3 0 0
Tissue inhibitor of metalloproteinase 1 Timp1 30 3 N o 1 2 0 0
Transferrin Tsf 20 2 N o 0 1 1 0
Vimentin Vim 20 2 N o 0 2 0 0
Apolipoprotein ApoE 43 1 Y e s 3 0 1 0
Ca(2+)/calmodulin-dependent protein kinase II CaMKII 41 3 Y e s 2 1 1 0
Cabonic anhydrase CA 21 1 Y e s 0 0 2 0
CD 99 antigen CD99 21 1 Y e s 0 0 1 1
Glyceraldehyde phosphate dehydrogenaase GAPDH 32 1 Y e s 2 1 0 0
Glycoprotein 65 21 1 Y e s 1 1 0 0
Growth arrest and DNA damage-inducible
protein 45
GADD45 30 3 Y e s 0 3 0 0
Laminin receptor 1 Lamr1 21 1 Y e s 0 1 1 0
Metallothionein 1 Mt1 3 1 2 Yes 1 2 0
Ornithine decarboxylase Oda 21 1 Y e s 0 1 1 0
Peptidylprolyl isomerase B (cyclophilin B) Ppib 20 2 Y e s 0 2 0 0
Platelet activation factor acetylhydrolase Pafah 31 2 Y e s 0 2 1 0
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review. The gene ontology classiﬁcation of cellular component,
biological process and molecular function has been used for func-
tionalclassiﬁcationbythemajorityofauthorswhereasseveralhave
utilized functional groups described previously in the literature
including immediate early genes/transcription factors, calcium
homeostasis, intra/extracellular signaling, synaptic/vesicular, mor-
phology, cell cycle/fate, injury/survival, metabolism and unknown.
A list of the most prominent biological process regulated as
described by each author is seen in Table 4. It is clear that there is a
wide range of biological processes involved in the epileptogenic
process. These include basic cellular metabolism, regulation of
transcription, protein processing, synaptic transmission, response
to injury/cell death and regeneration and immune response.
The different time frames of the analysis of the gene expression
also contribute to the differences to the proﬁling results.Transcrip-
tional changes immediately following seizures will encompass the
responsetohyperthermia,mildhypoxiaorhypoglycemia,andeven
direct trauma from any cerebral or truncal impacts. This contrasts
with gene expression during the latent phase of epileptogenesis
whereby a period of recovery with substrate replenishment and
remodeling occurs, and during the chronic epileptic states seen in
human studies. Numerous studies have demonstrated the transient
nature of transcriptional changes within their own epileptogenesis
model, let alone between different models (57, 63, 110).
Lukasiuk et al have recently presented in abstract form and in a
review article, an extension to their previous analysis of gene
expression during epileptogenesis. Identiﬁcation of highly repre-
sented functional classiﬁcation as well as individual genes that
appeared across data sets was performed with cell death and sur-
vival, neuronal plasticity and immune response as the most promi-
nent. Seventy individual genes were identiﬁed to be consistently
regulated across at least three studies using speciﬁc time-point
analyses (64, 65). Our data indicates only 22 genes consistently
regulated across at least three studies. This difference is explained
by the inclusion of animal models of traumatic head injuries in the
analysis by Lukasiuk et al that we did not include.The justiﬁcation
for their inclusion is the initial hit theory whereby an early insult,
be it ischemic, traumatic or infective, sets into motion a series of
molecular changes that lead into the latency period before chronic
epilepsy. However, recent ﬁgures suggest only 2% to 5% of trau-
matic brain injury cases will develop epilepsy (75). Second, post-
traumatic seizures are more commonly a result of cerebral contu-
sions leading to scarring and altered neuronal circuitry rather than
the classical MTLE syndrome. Filtering out the head injury papers
from Lukasiuk et al’s study leaves only four consistently regulated
genes, three of which are included in our list of regulated genes
(Gadd45a, Ctsd, Ctss, Zfp36).The last gene, zinc ﬁnger protein 36
(zfp36)isonlyreporteddifferentiallyexpressedindifferentarmsof
thesamestudybyBeckeret alandwasexcludedfromouranalysis.
Table 3. Continued.
Gene name Abbreviation Reports Platform Conﬂicting Epilepsy model
SAGE MA Electrical
kindling
Chemical
kindling
Human IER
Protein kinase C b PrkCB 2 0 2 Yes 0 2 0
Proteolipid protein 1 Plp 21 1 Y e s 1 0 1 0
Thymosin beta Tmbx 43 1 Y e s 2 1 1 0
Serum/glucocorticoid regulated kinase Sgk 2 0 2 Unknown 1 1 0 0
CD 14 antigen CD14 2 0 2 Unknown 1 1 0 0
CD 74 antigen CD74 2 0 2 Unknown 1 0 1 0
Corticotropin releasing hormone CRH 2 0 2 Unknown 1 1 0 0
GABA(A) receptor associated protein GABARAP 2 1 1 Unknown 1 0 0 1
Galanin Gal 3 0 3 Unknown 1 2 0 0
Glutamate receptor, ionotropic, N-methyl
D-aspartate 2A
Grin2A 2 0 2 Unknown 1 0 1 0
Homer homolog 1 Homer 3 DD, MPSS 1 Unknown 3 0 0 0
Neuritin Nrn 2 0 2 Unknown 0 2 0 0
Neuropeptide Y Npy 4 0 4 Unknown 1 3 0 0
Nuclear factor of kappa light chain gene
enhancer in B-cells inhibitor, alpha
Nfkbia 2 0 2 Unknown 1 1 0 0
Peptidylglycin-alpha-amidating
monooxygenase
PAM 2 0 2 Unknown 0 2 0 0
Prostaglandin-endoperoxide synthase 2 Ptgs2 2 0 2 Unknown 1 1 0 0
Secreted phosphoprotein 1 Spp1 2 0 2 Unknown 1 1 0 0
Signal transducer and activator of
transcription 3
Stat3 2 0 2 Unknown 1 1 0 0
Somatostatin Sst 2 0 2 Unknown 1 1 0 0
Synaptophysin Syp 2 0 2 Unknown 2 0 0 0
Syndecan 4 Sdc4 2 0 2 Unknown 1 1 0 0
VGF nerve growth factor inducible Vgf 3 0 3 Unknown 1 2 0 0
b2-microglobulin b2m 2 0 2 Unknown 2 0 0 0
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the mesial temporal lobe regions may contribute to this issue. In
particular, the anatomical subregions of the hippocampus demon-
stratebothhistologicalandfunctionaldifferencesintheircomposi-
tion and response to certain conditions.Whereas CA1 and CA3 are
considered integral to the transmission of input signals, CA2 is
considered a transitional zone with no clear function and the
dentategyrusisconsideredthemaininputpathwayintothehippoc-
ampus, receiving afferents itself from the entorhinal cortex via the
perforant pathway (31). Increasing interest in gene expression pro-
ﬁling between hippocampal subﬁelds has suggested a molecular
basis underlying the previously deﬁned anatomic subregions of the
hippocampus(112).Thismayfurtherimproveunderstandingofthe
differing histopathological responses described earlier.
Few reports have attempted to stratify global gene expression
proﬁles in terms of hippocampal subﬁelds. Indeed, of the reviewed
articles, only three reported comparisons between subregions of
the brain. Reasons for this may include the large amounts of start-
ingmRNAneededforglobalgeneexpressionplatformsingeneral,
or the difﬁculty in isolating individual subﬁelds. The use of stereo
dissection or laser microdissection to accurately isolate different
hippocampalsubregionsasperformedbyBeckeret al,Datsonet al
and Torres-Munoz et al have challenged these notions. This tech-
nique has been described to allow direct microscopic identiﬁcation
of speciﬁc cell types without appreciable loss of their DNA or
RNA. Furthermore microarray analysis was able to be performed
on the limited amount of mRNA extracted using double round
ampliﬁcation to provide sufﬁcient material (4, 17, 99). Marked
differences (>700 genes) were found in the hippocampal response
to chronic glucocorticoid exposure between CA3 and the dentate
gyrus; however, 79 genes reliably identiﬁed in individual subﬁelds
were virtually undetectable when looking at whole hippocampal
specimens.The practice of analyzing gross or pooled hippocampal
specimens fails to take into account these obvious differences and
may skew ensuing results.
Although global expression proﬁling has the advantages of
being time efﬁcient in analyzing large portions of the transcrip-
tome, there are limitations to the sensitivity and accuracy. It is well
documented that SAGE may inconsistently detect low abundance
transcripts leaving small genomic expression changes induced by
the experimental model or disease undetected. This is evident
in examining the epilepsy studies discussed above with each
generated database containing 5000 to 14 000 unique tags only, a
signiﬁcantdecreasefromtheestimatedsizeoftheentirehippocam-
pal transcriptome being over 30 000 (16, 26). Furthermore, the
sequencing error of SAGE is estimated at an average of 1% per
base because of the fact they utilize a single-pass sequence in data
processing. This accumulates to roughly 10% per 100 base pairs,
leading to lower correct tags counts and artiﬁcially inﬂate the tag
counts of already established tags or establish a count of a tag that
does not exist. Microarray studies have also been shown to demon-
strate signiﬁcant variations even under the same experimental con-
ditions.Assuch,validationofglobalexpressionproﬁlingresultsby
independent methods, such as real-time polymerase chain reaction
(PCR), Northern/Western blotting and immunohistochemical
methods, is crucial. In our experience, a signiﬁcant decrease in the
number of differentially expressed genes is demonstrated when
validating SAGE results using quantitative real-time polymerase
chain reaction (qRT-PCR) with a custom-made, low-density array
chip of 94 signiﬁcant genes as indicated by SAGE (82).
Table 4. Biological processes. Abbreviations: EC = endothelial cell; ECM = extracellular matrix; PG = prostaglandin.
Biological process Author
Arai Elliott Gorter Hendriksen Hunsberger Jamali Liang Lukasiuk Tang Wang
Axonal growth and proliferation ✓
Cell adhesion ✓
Cell cycle progression ✓
Cell damage, axonal growth and regeneration ✓
Cell death ✓
Cellular metabolism ✓✓ ✓ ✓
Cellular transport ✓
Coagulation pathway ✓
Cytoskeletal/ECM organization ✓
EC signaling ✓
ECM remodeling ✓✓
Gliosis ✓
Immune response ✓✓ ✓ ✓
Injury response/cell survival ✓
Membrane transport ✓
Morphology ✓
Neuronal plasticity ✓
Neurotransmission ✓
PG synthesis ✓
Protein processing ✓✓
Signal transduction ✓
Synaptic transmission ✓ ✓
Transcriptional regulation ✓✓
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date results of global expression proﬁling. Translation into func-
tional proteins represents the ﬁnal pathway of genomic regulation.
Quantifying the proteomic changes specimens through immunop-
eroxidase stainings and in situ hybridizations will not only
complete the interrogation process, but also give insights into
region-speciﬁc changes that may have been missed in interrogation
of gross hippocampal, possibly negating the requirement for
microdissection of hippocampal subregions (Figure 3).
In terms of gene expression platforms, the laboratory conditions
play a vital role in the reproducibility of results. It is not unusual
for the same experiments performed on different days to produce
differing results. Similarly, experiments performed by separate sci-
entists on the same days will also often produce differing results.
Subtle variations in the complementary tags used to interrogate the
transcriptome can also cause biased results. Speciﬁcally, selection
ofcDNAprobesetsonmicroarraycardsortheuseofmodiﬁcations
oftheSAGEtechniquesuchasLongSAGEaddsmorepotentialfor
a varied result.
Whatthenaretheadvantagesofglobalexpressionproﬁling?The
advent of these technologies in the mid-1990s heralded a new
excitementintothepossibilitiesofmolecularbiologicalresearch.It
allowed researchers to access the diverse levels of biological pro-
cesses in its entirety, from primary DNA sequences in coding and
regulatory regions, to RNA expression in response to the physi-
ological or diseased environment, to proteomic interactions and
localizations. The sheer power of simultaneously interrogating
thousands of genes enables the acquisition of global pictures of
biological processes that would otherwise be out of reach utilizing
traditional gene-to-gene approaches.
Prior to global expression proﬁling, laboratory research was
being driven by theories and hypotheses developed from meticu-
lously analyzed pathways or the occasional spontaneous brain
wave. The formulation of these theories in the history of epilepsy
research have resulted in much interest in the neural imbalance of
excitatory/inhibitory control, or the involvement of ionic chan-
nels and aberrant neuronal synapses in the epileptogenic pro-
cesses (97). Indeed, numerous laboratories have published
insightful papers documenting a net excitatory imbalance in
MTLE models (14, 22, 84). More recently two microarray studies
revealed conﬁrmatory ﬁndings with the downregulation of
gamma-aminobutyric acid-associated receptors and the upregula-
tion of glutamate-associated receptors in the kainite model of epi-
leptogenesis as well as chronic human MTLE (3, 44). What is not
evident in the literature are the situations where there have been
failed hypotheses resulting in a laboratory and scientiﬁc losses in
terms of time, personnel and ﬁnance. The use of global proﬁling
platforms to guide hypotheses may be a viable option to mini-
mize these situations.
The advantage in global expression proﬁling is the development
of a broad understanding of the mechanisms underlying the
process. It is the accumulation of the supportive data gathered
from functional classes that enables more robust hypotheses to be
formedandtested.Inturnthisallowsfurtherfocussedresearchinto
speciﬁc genes or functional classes as has already been performed
by several laboratories (42, 80). Novel treatment strategies may be
identiﬁed from the identiﬁcation of the involvement of functional
groups with development of new pharmacological agents targeting
the speciﬁc biological process.
The publication of comparable gene libraries produced using
global expression proﬁling methods also allows indirect interroga-
tion between epilepsy and other disorders. Identiﬁcation of com-
monality genes across disorders may provide a greater understand-
ing of the aetiological or consequential effect of a regulated
gene/process. Detection of common pathways through which each
disorder is propagated may allow cross-over treatment between
disorders giving new insight and treatment options.
CONCLUSIONS
Global expression proﬁling during epileptogenesis allows a greater
understanding of the broad mechanisms underlying the epileptic
process. It demonstrates speciﬁc genomic changes operating in
concertwiththeentiremolecularenvironment,therebyopeningthe
doors to further research into possible causative pathways and
functions through gene ontology annotations of cellular compo-
nents, biological processes and molecular functions. In addition,
theavailabilityoflarge-scalelibrariesproducedusinguniformpro-
tocols allows the comparisons of commonality genes within other
disorders apart from epilepsy potentially identifying reactive
general genomic changes, shared pathways of action or speciﬁc
causative genes. There is also the potential for discovery of novel
genes not previously described with SAGE resulting in new
hypothesesandtheoriesintothepathogenesisofepilepsyaswellas
the potential to guide new therapeutic treatments in epilepsy as
well as other disorders, neural or non-neural.
However, the most exciting aspect of global gene expression
proﬁling is the general starting point of the research study. Previ-
ously, investigations into speciﬁc genes were performed based on
previous studies or individual hypotheses. The use of global
expression proﬁling allows the entire genome to be studied with
hypotheses developed following this. In this manner, future
researchhypothesesaregeneratedfromscienceratherthanhypoth-
eses leading to science, a situation that must lend itself to greater
transparency in laboratory research.
It is vitally important that further research into epileptogenesis
builds on prior knowledge and pitfalls. It is the opinion of our
laboratory that the entire process of molecular transcription and
translation be interrogated with validation of global expression
proﬁling results utilizing qRT-PCR followed by proteomic proﬁl-
ing using any combination ofWestern blotting, immunoperoxidase
staining and in situ hybridization. Focusing genomic proﬁles into
speciﬁc anatomical regions may enable causative molecular path-
ways to be identiﬁed and allow greater understanding of the histo-
logical changes, particular in the situation of HS associated MTLE
whereby disagreement remains over the cause or effect of the
pathological changes.
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